Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
JBIO · Why this verdict
Why Jade Biosciences (JBIO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stated risk/reward is strongly favorable, with upside to the analyst-based price target near 96% against about 7% downside to the stop-loss level, producing an asymmetry ratio of roughly 6.4. Targets | The favorable asymmetry should hold or widen if shares continue to close the gap toward the price target without downside accelerating. | →Stable |
| CounterAnalyst coverage is described as light, which the data says dampens the signal behind the price target and the implied upside. | ||
Overall quality screens below the minimum threshold, with the data flagging general quality concerns despite conservative debt levels noted elsewhere. Quality breakdown | The quality score would need to climb back above the minimum floor for the underlying business-quality concern to be resolved. | →Stable |
| CounterConservative debt levels give the company a cleaner balance sheet than the low quality score alone suggests, which could support quality improving over time. | ||
The stock is overbought with an RSI of 77 while still trading above its 200-day moving average, indicating a strong but potentially stretched uptrend. Momentum breakdown | RSI cooling from overbought levels while the stock holds above its 200-day moving average would support a healthy continuation of the uptrend. | →Stable |
| CounterAn RSI reading this elevated often precedes a near-term pullback, which could test whether the move above the 200-day moving average holds. | ||
Options positioning shows an elevated put/call ratio of about 32.75 alongside implied volatility near 115%, signaling heavy hedging or bearish options activity relative to calls. Risk breakdown | A put/call ratio moving back toward parity and implied volatility declining would indicate the elevated options risk is easing. | →Stable |
| CounterSuch an extreme put/call skew on a lightly covered biotech name may reflect thin options volume rather than a strong directional signal. | ||
The company has missed earnings estimates in three of its last four quarters, with an average surprise of about -140%, including one miss of nearly -490%. Earnings | A return to consistently meeting or beating estimates over the next several quarters would ease the earnings-execution concern. | →Stable |
| CounterThe quarter immediately preceding the latest miss was a beat with a surprise over 28%, showing the company can exceed expectations when conditions align. | ||
The stated risk/reward is strongly favorable, with upside to the analyst-based price target near 96% against about 7% downside to the stop-loss level, producing an asymmetry ratio of roughly 6.4.
→StableTargets
- Expectation
- The favorable asymmetry should hold or widen if shares continue to close the gap toward the price target without downside accelerating.
CounterAnalyst coverage is described as light, which the data says dampens the signal behind the price target and the implied upside.
Overall quality screens below the minimum threshold, with the data flagging general quality concerns despite conservative debt levels noted elsewhere.
→StableQuality breakdown
- Expectation
- The quality score would need to climb back above the minimum floor for the underlying business-quality concern to be resolved.
CounterConservative debt levels give the company a cleaner balance sheet than the low quality score alone suggests, which could support quality improving over time.
The stock is overbought with an RSI of 77 while still trading above its 200-day moving average, indicating a strong but potentially stretched uptrend.
→StableMomentum breakdown
- Expectation
- RSI cooling from overbought levels while the stock holds above its 200-day moving average would support a healthy continuation of the uptrend.
CounterAn RSI reading this elevated often precedes a near-term pullback, which could test whether the move above the 200-day moving average holds.
Options positioning shows an elevated put/call ratio of about 32.75 alongside implied volatility near 115%, signaling heavy hedging or bearish options activity relative to calls.
→StableRisk breakdown
- Expectation
- A put/call ratio moving back toward parity and implied volatility declining would indicate the elevated options risk is easing.
CounterSuch an extreme put/call skew on a lightly covered biotech name may reflect thin options volume rather than a strong directional signal.
The company has missed earnings estimates in three of its last four quarters, with an average surprise of about -140%, including one miss of nearly -490%.
→StableEarnings
- Expectation
- A return to consistently meeting or beating estimates over the next several quarters would ease the earnings-execution concern.
CounterThe quarter immediately preceding the latest miss was a beat with a surprise over 28%, showing the company can exceed expectations when conditions align.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Jade Biosciences screens as attractively valued with a heavily favorable stated risk/reward and a stock still trading above its 200-day moving average, but that sits against below-floor quality scores, a stretched overbought reading, unusual options positioning, and a recent run of earnings misses.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.6 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 88)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
8.4/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.5 |
| Analyst rating | 7.9 |
| Price target | 10.0 |
- ▸LLM news sentiment: +0.50 (n=1)
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 115%
Insider
5.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.9 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
6.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.4 |
| support resistance | 1.0 |
| 52w position | 6.1 |
Risk (lower is worse)
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.0 |
| days to cover | 6.3 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| debt equity | 10.0 |
- ▸Elevated put/call: 32.75
- ▸High IV: 90%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:4.7>=4.5
- ASYMMETRY:5.8>=1.5
- INSIDER:OK
- EARNINGS_PROXIMITY:37d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- MOMENTUM:4.7<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
5.80
Upside
+87.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.3B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 8.4, and Peer rank at 6.1; the weakest are Quality at 2.5, Catalyst at 3.0, and Technical at 3.2. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 5.80 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Favorable Risk Reward Skew
Trip ifThe risk/reward ratio compresses below 1.5x from the current 6.41x.
- P2Below Floor Quality Concerns
Trip ifThe quality score rises above 4.0 from the current 2.5.
- P3Overbought Uptrend Above 200ma
Trip ifThe stock falls below its 200-day moving average, reversing the current above-trend position.
- P4Elevated Options Skew Risk
Trip ifThe put/call ratio falls below 5 from the current 32.75.
- P5Recent Earnings Miss Pattern
Trip ifEPS surprise turns positive (exceeds 0%) for 2 consecutive quarters.